evidence: DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group
intervention: Dual release ciprofloxacin for inhalation (DRCFI)
comparator: Placebo
outcome: Requirement of antibiotics for pulmonary exacerbation